Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-946 Phase IIa/IIb study in anemia due to lower-risk myelodysplastic syndromes
ISRCTN10304854Phase 2Active, not recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of tebapivat in myelodysplastic syndrome (MDS) (4 arms), sponsored by Agios Pharmaceuticals. Started Nov 2023; status: active, not recruiting.
02
Drugs
tebapivat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN10304854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10304854.